JP7418353B2 - トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用 - Google Patents

トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用 Download PDF

Info

Publication number
JP7418353B2
JP7418353B2 JP2020563691A JP2020563691A JP7418353B2 JP 7418353 B2 JP7418353 B2 JP 7418353B2 JP 2020563691 A JP2020563691 A JP 2020563691A JP 2020563691 A JP2020563691 A JP 2020563691A JP 7418353 B2 JP7418353 B2 JP 7418353B2
Authority
JP
Japan
Prior art keywords
methyl
triazolo
trimethyl
phenyl
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020563691A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019215316A5 (https=
JP2021523177A5 (https=
JP2021523177A (ja
Inventor
ゴールドバーグ，フレデリック・ウルフ
ティング，アッティラ・クアン・ツイ
ラモント，ギリアン・マックレガー
ブタール，デヴィッド
ケトル，ジェイソン・グラント
Original Assignee
ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド filed Critical ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド
Publication of JP2021523177A publication Critical patent/JP2021523177A/ja
Publication of JPWO2019215316A5 publication Critical patent/JPWO2019215316A5/ja
Publication of JP2021523177A5 publication Critical patent/JP2021523177A5/ja
Application granted granted Critical
Publication of JP7418353B2 publication Critical patent/JP7418353B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020563691A 2018-05-11 2019-05-10 トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用 Active JP7418353B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670075P 2018-05-11 2018-05-11
US62/670,075 2018-05-11
PCT/EP2019/062020 WO2019215316A1 (en) 2018-05-11 2019-05-10 Triazolopyrimidine compounds and their use in treating cancer

Publications (4)

Publication Number Publication Date
JP2021523177A JP2021523177A (ja) 2021-09-02
JPWO2019215316A5 JPWO2019215316A5 (https=) 2022-05-16
JP2021523177A5 JP2021523177A5 (https=) 2022-05-16
JP7418353B2 true JP7418353B2 (ja) 2024-01-19

Family

ID=66484070

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020563691A Active JP7418353B2 (ja) 2018-05-11 2019-05-10 トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用

Country Status (16)

Country Link
US (3) US11084827B2 (https=)
EP (2) EP4134368A1 (https=)
JP (1) JP7418353B2 (https=)
KR (1) KR102863374B1 (https=)
CN (3) CN112469721B (https=)
AR (1) AR115384A1 (https=)
AU (1) AU2019264826B2 (https=)
BR (1) BR112020023068A2 (https=)
CA (1) CA3099579A1 (https=)
DK (1) DK3790879T3 (https=)
ES (1) ES2927244T3 (https=)
MX (1) MX2020012058A (https=)
PT (1) PT3790879T (https=)
TW (1) TWI823932B (https=)
UY (1) UY38228A (https=)
WO (1) WO2019215316A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途
WO2021174176A1 (en) * 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
US20230192704A1 (en) * 2020-05-21 2023-06-22 Teon Therapeutics, Inc. Monocarboxylic acid transporter 4 (mct4) modulators and uses thereof
WO2021249969A1 (en) * 2020-06-10 2021-12-16 Merck Patent Gmbh Combination product for the treatment of cancer diseases
WO2022090527A1 (en) 2020-11-02 2022-05-05 Ares Trading S.A. Combination treatment of cancer
WO2022243573A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 1,2,4-triazolo[1,5-a]pyrimidine-based slc16a3 inhibitors and their therapeutic use
WO2022243574A1 (en) 2021-05-21 2022-11-24 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 3-(phthalazin-1-yl)benzenesulfonamide-based slc16a3 inhibitors and their therapeutic use
CN120699024A (zh) * 2024-03-25 2025-09-26 北京福元医药股份有限公司 Mct4抑制剂及其药物组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
WO2017196936A1 (en) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0300119D0 (sv) 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
DE102005034905A1 (de) 2005-07-26 2007-02-01 Federal-Mogul Nürnberg GmbH Verfahren zur Herstellung eines Kolbens für einen Verbrennungsmotor sowie Kolben für einen Verbrennungsmotor
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CA2974697A1 (en) * 2015-01-22 2016-07-28 The Scripps Research Institute Pyrimidine-2,4-(1h,3h)-dione derivatives and pharmaceutical compositions thereof and their use as inhibitors of monocarboxylate transporters
BR112017026535B1 (pt) * 2015-06-12 2023-12-19 Vettore, LLC Composto e composição farmacêutica
TWI823932B (zh) * 2018-05-11 2023-12-01 中國大陸商迪哲（江蘇）醫藥有限公司 三唑并嘧啶化合物及其在治療癌症中之用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072746A1 (en) 2001-10-16 2004-04-15 Michael Sullivan Inhibitors of monocarboxylate transport
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JP2018502874A (ja) 2015-01-22 2018-02-01 ザ スクリプス リサーチ インスティテュート プテリジンジオンモノカルボン酸トランスポータ阻害薬
WO2017196936A1 (en) 2016-05-12 2017-11-16 Regents Of The University Of Minnesota Indole and indazole cyanocinnamate compounds and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112020023068A2 (pt) 2021-02-09
EP4134368A1 (en) 2023-02-15
EP3790879B1 (en) 2022-06-29
AR115384A1 (es) 2021-01-13
CN112469721A (zh) 2021-03-09
EP3790879A1 (en) 2021-03-17
ES2927244T3 (es) 2022-11-03
US20210087196A1 (en) 2021-03-25
CN115028636A (zh) 2022-09-09
WO2019215316A1 (en) 2019-11-14
PT3790879T (pt) 2022-08-26
AU2019264826A1 (en) 2020-11-26
CN115028637A (zh) 2022-09-09
US12503473B2 (en) 2025-12-23
CA3099579A1 (en) 2019-11-14
KR102863374B1 (ko) 2025-09-22
US11851432B2 (en) 2023-12-26
AU2019264826B2 (en) 2024-05-23
US11084827B2 (en) 2021-08-10
US20210340150A1 (en) 2021-11-04
KR20210013078A (ko) 2021-02-03
CN115028637B (zh) 2024-03-22
DK3790879T3 (da) 2022-08-29
US20240217980A1 (en) 2024-07-04
JP2021523177A (ja) 2021-09-02
TW202015674A (zh) 2020-05-01
TWI823932B (zh) 2023-12-01
CN112469721B (zh) 2022-06-07
MX2020012058A (es) 2021-02-26
UY38228A (es) 2019-10-31

Similar Documents

Publication Publication Date Title
JP7418353B2 (ja) トリアゾロピリミジン化合物およびがんの処置におけるそれらの使用
EP3140303B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
EP3053923B1 (en) Triazolopyrazine derivatives as tyrosin kinase inhibitors
CA3219002A1 (en) Substituted pyrazolo[1,5-a]pyrimidine-7-amine compounds as cdk inhibitors and their therapeutic use
CN117693503A (zh) 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
AU2017237394A1 (en) Cinnolin-4-amine compounds and their use in treating cancer
RU2793249C2 (ru) Триазолпиримидиновые соединения и их применение в лечении рака
HK40088382A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40047025B (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080418A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417A (en) Triazolopyrimidine compounds and their use in treating cancer
HK40080417B (zh) 三唑并嘧啶化合物和其用於治疗癌症的用途
HK40047024A (en) Triazolopyrimidine compounds and their use in treating cancer
HK1232528B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1232528A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220502

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230919

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240109

R150 Certificate of patent or registration of utility model

Ref document number: 7418353

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150